Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

Stocks tried to stage a weak rally to close the week after the latest reading on inflation came in line with expectations. However, the longer-term direction for stocks may come down to whether ...

Financial markets grappled with a storm of political maneuvering around trade, taxes, and regulation, stoking some investor ...

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $28.87, denoting a +0.7% change from the preceding trading day.

We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...

Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But ...

Weight-loss drugs like Wegovy and Zepbound are proving incredibly lucrative, and analysts project this field will grow by leaps and bounds through the end of the decade. Viking Therapeutics is looking ...

Global Retirement Partners LLC trimmed its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 19.8% during the ...

Market analysts are increasingly highlighting mid-cap stocks as a potentially attractive investment opportunity, particularly ...

State of New Jersey Common Pension Fund D boosted its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 8.5% during the fourth quarter, according to its most recent Form 13F filing ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

However, there are many contenders in the works. One of the most promising GLP-1 contenders is VK2735, a dual GLP-1/GIP ...